Screening for hepatitis C in injecting drug users: A cost utility analysis

Journal of Public Health

Volumn 26, Issue 1, 2004, Pages 61-71

  Stein, Ken ^a   Dalziel, Kim ^a   Walker, Andrew ^b   Jenkins, Becky ^c   Round, Alison ^a   Royle, Pam ^d  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c N and E Devon Health Authority   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cost utility; Drug users; Hepatitis C; Screening

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG MISUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; MASS SCREENING; META ANALYSIS; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNITED KINGDOM;

EID: 2942741035     PISSN: 17413842     EISSN: None     Source Type: Journal    
DOI: 10.1093/pubmed/fdh109     Document Type: Review

References (37)

1. European Association for the Study of the Liver (EASL). EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 956-961.
2. Centers for Disease Control (CDC). Recommendations for the prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb Mortal Wkly Rep 1998; 47: 1-39.
3. American Academy of Pediatricians. Hepatitis C virus infection. Pediatrics 1998; 101: 481-485.
4. Galmiche JP. French consensus conference on hepatitis C: screening and treatment. Gut 1998; 42: 892-898.
5. The Advisory Council on the Misuse of Drugs. Reducing drug related deaths. London: The Stationery Office, 2000.
6. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alpha and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Hlth Technol Assess 2000; 4: 1-67.
7. National Institute for Clinical Excellence (NICE). Guidance on the use of ribavirin and interferon alpha for chronic hepatitis C. London: NICE, 2000.
8. Serfaty M, Lawrie A, Smith B, et al. Risk factors and medical follow up of drug users tested for hepatitis C - can the risk of transmission be reduced? Drug Alcohol Rev 1997; 16: 339-347.
9. The Government Actuary's Department. Interim life tables: expectation of life, Great Britain - based on data for the years 1997-1999. [On-line.] www.gad.gov.uk/policy_and_stats/life_tables.htm.
10. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
11. Bacosi M, Patsouri M, Miglioresi, L, et al. Combined treatment of HCV infection: is there a need for meta-analysis? Hepatol Res 2001; 20: 359-371.
12. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alpha with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. Br Med J 2001; 323: 1151-1155.
13. Ishizuka M. Economic evaluation of health care program for hepatitis C virus antibody screening. Nippon Koshu Eisei Zasshi 1999; 46: 447-465.
14. Lapane KL, Jakiche AF, Sugano D, Weng CS, Carey WD. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 1998; 93: 591-596.
15. Kaur S, Rybicki LB, et al. Performance characteristics and results of a large-scale screening programme for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. Hepatology 1996; 24: 979-986.
16. Desenclos JC, Dubois F, Mariotte N, Goudeau A. Faut-il depister l'hepatite C? Analyse des strategies de depistage oriente de l'infection par le virus de l'hepatite C. [Should hepatitis C be screened? Analysis of oriented screening strategies for hepatitis C virus infection.] Gastroenterol Clin Biol 1997; 21: S25-S32.
17. Rotily M, Loubiere S, Nixon J, et al. Faut-il depister l'hepatite C? Analyse socio-economique de differentes strategies de depistage de l'hepatite chronique C dans la population franqaise. [Should hepatitis C be screened? Socioeconomic analysis of different screening strategies for chronic hepatitis C in French population.] Gastroenterol Clin Biol 1997; 21: S33-S40.
18. Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J Med Screen 1999; 6: 124-131.
19. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001; 94: 153-158.
20. Cotler SJ, Patil R, McNutt RA, et al. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am J Gastroenterol 2001; 96: 2730-2736.
21. Hartnoll R, Lewis R, Mitcheson M, Bryer S. Estimating the prevalence of opioid dependence. Lancet 1985; 203-205.
22. Department of Health. Statistics from the Regional Drug Misuse Databases on drug misusers in treatment in England, 2000/01. Statistical bulletin. London: DoH, 2001.
23. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-215.
24. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345: 215-217.
25. Edeh J, Spalding P. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England. J Publ Hlth Med 2000; 22: 531-539.
26. Department of Health. Prevalence report of the Unlinked Anonymous Prevalence Monitoring Programme. London: DoH, 2000.
27. Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepatitis 2001; 8: 87-95.
28. Roche Diagnostics Corporation. COBAS AMPLICOR Hepatitis C virus test, version 2.0 (Rev 3.0). England, Roche Diagnostics Corporation, 1999.
29. Foster GR, Goldin RD, Main J, et al. Management of chronic hepatitis C: clinical audit of biopsy based managment algorithm. Br Med J 1997; 315: 453-458.
30. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000; 14: 543-548.
31. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-355.
32. Young TA, Longworth L, Ratcliffe J. Economic evaluation of the liver transplant programme in England and Wales: survival on the waiting list, post transplant, and estimated survival in the absence of transplantation. Final Report to the Department of Health. Uxbridge: Brunel University, 2000.
33. Barbaro G, Di Lorenzo G, Belloni G, et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicentre, randomized, controlled clinical study. Am J Gastroenterol 1998; 93: 2445-2451.
34. Weinstock HS, Bolan G, Reingold AL, Polish LB. Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases. JAMA 1993; 269: 392-394.
35. Smyth BP, Keenan E, O'Connor JJ. Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic. Ir J Med Sci 2000; 169: 129-132.
36. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481.
37. Davis GL, Esteban MR, Rustgi V, Hoefs J, Gordon SC. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.